{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T20:23:20Z","timestamp":1787516600651,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470227"],"award-info":[{"award-number":["82470227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272060"],"award-info":[{"award-number":["82272060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004204","name":"Tongji University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.acra.2026.04.019","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:18:59Z","timestamp":1777943939000},"page":"4083-4095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MRI Features Associated with Plasma ctDNA Positivity in Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Yulan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-4496","authenticated-orcid":false,"given":"Aijun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.acra.2026.04.019_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.acra.2026.04.019_bib3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","author":"Pentsova","year":"2014","journal-title":"J Neurooncol"},{"issue":"26","key":"10.1016\/j.acra.2026.04.019_bib6","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.acra.2026.04.019_bib7","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.acra.2026.04.019_bib8","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","article-title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","volume":"28","author":"Gleeson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.acra.2026.04.019_bib10","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3324\/haematol.2021.278559","article-title":"Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature","volume":"159","author":"Guirguis","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.acra.2026.04.019_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103756","article-title":"The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis","volume":"176","author":"Lin","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.acra.2026.04.019_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.acra.2026.04.019_bib14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","volume":"137","author":"Ollila","year":"2021","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.acra.2026.04.019_bib15","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.acra.2026.04.019_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.acra.2026.04.019_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Ferreri","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.acra.2026.04.019_bib18","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.acra.2026.04.019_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"issue":"346","key":"10.1016\/j.acra.2026.04.019_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-025-01673-7","article-title":"Circulating tumor DNA in lymphoma: technologies and applications","volume":"18","author":"Fu","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","article-title":"Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance","volume":"22","author":"Stejskal","year":"2023","journal-title":"Mol Cancer"},{"issue":"45","key":"10.1016\/j.acra.2026.04.019_bib23","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.acra.2026.04.019_bib24","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.acra.2026.04.019_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41375-024-02279-7","article-title":"Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma","volume":"38","author":"Liang","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.acra.2026.04.019_bib26","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.acra.2026.04.019_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.acra.2026.04.019_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acra.2026.04.019_bib29","unstructured":"TCIA: VASARI Research Project. Cancer Genome Atlas. 2020. Available at: \u3008https:\/\/wiki.cancerimagingarchive.net\/display\/Public\/VASARI+Research+Project\u3009. Accessed January 19, 2024."},{"issue":"5","key":"10.1016\/j.acra.2026.04.019_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/cancers16050844","article-title":"Modeling the effect of spatial structure on solid tumor evolution and circulating tumor DNA composition","volume":"16","author":"Rachman","year":"2024","journal-title":"Cancers"},{"issue":"224","key":"10.1016\/j.acra.2026.04.019_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.acra.2026.04.019_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.acra.2026.04.019_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.devcel.2020.10.011","article-title":"Mechanical adaptability of tumor cells in metastasis","volume":"56","author":"Gensbittel","year":"2021","journal-title":"Dev Cell"},{"key":"10.1016\/j.acra.2026.04.019_bib34","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.acra.2026.04.019_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.acra.2026.04.019_bib36","first-page":"422","article-title":"Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial","volume":"19","author":"Tabouret","year":"2017","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.acra.2026.04.019_bib37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/neuonc\/noad177","article-title":"Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas","volume":"26","author":"Lauer","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226002904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226002904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T20:11:21Z","timestamp":1787515881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633226002904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1076633226002904"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2026.04.019","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI Features Associated with Plasma ctDNA Positivity in Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2026.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}